1MaeCollin M,Chiocea EA,Evans DG. Diagnostic criteria for schwannomatosis[J].Neurology,2005.1838-1845.doi:10.1212/01.WNL.0000163982.78900.AD.
2Antinheimo J,Sankila R,Carpen O. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas[J].Neurology,2000,(1):71-76.
3Kim DH,Hwang JH,Park ST. Schwannomatosis involving peripheral nervesi:a case report[J].Journal of Korean Medical Science,2006.1136-1138.doi:10.3346/jkms.2006.21.6.1136.
4Ferner BE,O'Doherty MJ. Neurofibroma and schwannoma[J].Current Opinion in Neurology,2002,(6):679-684.doi:10.1097/00019052-200212000-00004.
5Sestini R,Bocci C,Provenzano A. Evidence of a four-hit mechanism involving SMARCBI and NF2 in sehwannomatosis-associated schwannomas[J].Human Mutation,2008.227-231.doi:10.1002/humu.20679.
6Hedfield KD,Newnum WG,Bowers NL. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis[J].Journal of Medical Genetics,2008,(6):332-339.doi:10.1136/jmg.2007.056499.
7MacCollin M,Woodrin W,Kronn D. Sehwannomatosis:a clinical and pathologic study[J].Neurology,1996.1072-1079.
8MacCollin M,Willen C,Heinrich B. Familial sehwannomatosis:exclusion of the NF2 locus as the gerndine event[J].Neurology,2003.1968-1974.
9Evans DC,Mason S,Huson SM. Spinal and cutanous sehwannomatosis is U variant form of type 2 neurofibronmtosis:a clinical and molecular study[J].Journal of Neurology, Neurosurgery & Psychiatry,1997.361-366.doi:10.1136/jnnp.62.4.361.
10Gonzalez-Martinez T,Perez-Pinera P,Dias-Esnal B. S-100 proteins in the human periphend nervous system[J].Microscopy Research and Technique,2003.633-638.doi:10.1002/jemt.10304.
